UCLA Ronald Reagan Medical Center
Welcome,         Profile    Billing    Logout  
 47 Trials 
73 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schiller, Gary J
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies with Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Constellation Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/29
06/29
NCT04260698: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Active, not recruiting
3
36
US
omidubicel, NiCord
Gamida Cell ltd
Hematological Malignancies
05/25
05/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
BP1001-201-AML, NCT02781883: Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Recruiting
2a
108
US
BP1001 in combination with Ventoclax plus decitabine, Liposomal Grb-2, L-Grb-2, BP1001 plus decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia (AML)
12/24
12/24
NCT04231851: CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Active, not recruiting
2
30
US
Glasdegib, DAURISMO™, CPX-351, Daunorubicin and cytarabine, VYXEOS®
University of California, Irvine, Jazz Pharmaceuticals, Pfizer
Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
06/25
06/27
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
NCT06456463: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Recruiting
2
76
US, RoW
Tagraxofusp, Tag, Venetoclax, Ven, Azacitidine, Aza
Stemline Therapeutics, Inc.
Acute Myeloid Leukemia
02/28
02/30
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Active, not recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
KCP-8602-801, NCT02649790 / 2021-003810-38: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc, Karyopharm Therapeutics Inc.
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Hourglass Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN
Active, not recruiting
1/2
179
Europe, US
IMGN632
AbbVie
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
09/23
12/26
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with pomalidomide and dexamethasone for early line multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with pomalidomide and dexamethasone for early line multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
OPAL, NCT04329728: The Study: AVM0703 for Treatment of Lymphoid Malignancies

Recruiting
1/2
144
US
AVM0703, Supra-Pharmacologic Dexamethasone Phosphate
AVM Biotechnology Inc, Medpace, Inc.
Lymphoid Malignancies
04/25
06/25
NCT04774536: Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

Recruiting
1/2
9
US
CRISPR_SCD001
Mark Walters, MD, University of California, Los Angeles, University of California, Berkeley
Sickle Cell Disease
03/27
03/29
NCT02247843: Stem Cell Gene Therapy for Sickle Cell Disease

Active, not recruiting
1/2
4
US
βAS3-FB vector transduced peripheral blood CD34+ cells, Lenti/βAS3-FB
Donald B. Kohn, M.D., California Institute for Regenerative Medicine (CIRM)
Sickle Cell Disease
12/25
12/25
NCT04536792: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Completed
1
122
Europe, US
AG-946, AG-946 Matched Placebo
Agios Pharmaceuticals, Inc.
Healthy Volunteers, Anemia, Sickle Cell
12/23
12/23
BP1002-102-AML, NCT05190471: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Recruiting
1
48
US
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Liposomal Bcl-2; L-Bcl-2, Decitabine (in combination with BP1002), Decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
03/24
09/24
SENTI-202-101, NCT06325748: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Recruiting
1
21
US, RoW
SENTI-202, Fludarabine, Cytarabine (ara-C)
Senti Biosciences
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
09/25
08/40
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
CLN-049-001, NCT05143996: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Recruiting
1
60
US
CLN-049
Cullinan Oncology Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
08/25
11/25
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Olin, Rebecca
NCT03870750: Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Active, not recruiting
2/3
455
US
Supportive Palliative Care, Comfort Care, palliation, palliative care, palliative therapy, Palliative Treatment, Symptom Management, Symptoms Management, PA-Palliative Therapy, Clinical Management, Best Practice, standard of care, standard therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment, Survey Administration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder
12/25
12/25
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
Gonzalez, Nestor R
ANFIS, NCT04240119: Angiogenic Markers in Cerebrovascular Disease

Enrolling by invitation
N/A
300
NA
According to current clinical care standards
Cedars-Sinai Medical Center
Stroke, Transient Ischemic Attack, Atherosclerosis, Intracranial Arterial Stenosis, Moyamoya
07/30
12/30
NCT02910180: Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders

Recruiting
N/A
900
US
Cedars-Sinai Medical Center
Cerebrovascular Diseases, Ischemic Stroke, Repository
12/30
12/30
Buxbaum, James L
PERT-AP, NCT06477159: Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency

Recruiting
4
60
US
Pancrelipase Capsules, CREON
Ohio State University, University of Pittsburgh, University of Illinois Chicago, University of Southern California, New York University, AbbVie
Exocrine Pancreatic Insufficiency
12/26
07/27
NCT03087656: Antibiotics to Decrease Post ERCP Cholangitis

Recruiting
4
200
US
Ceftriaxone, Rocephin, Levofloxacin, Levaquin
University of Southern California
Cholangitis
02/24
02/24
NCT02476279: Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis

Completed
3
1950
Canada, US
Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement, Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
Medical University of South Carolina, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Post-ERCP Pancreatitis
01/23
01/23
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
NCT03103139: Endoscopic Stenting Across the Papilla Versus the Leak Site to Treat Bile Leak

Enrolling by invitation
N/A
92
US
Transpapillary Stent, Stent across bile leak
University of Southern California
Bile Leak
10/23
10/23
NCT02197351: Narrow Band Imaging for Gastric Neoplasia

Recruiting
N/A
220
Europe, US
White light biopsy, Protocolled, Narrow Band Imaging Guided Biopsy
University of Southern California, Universidade do Porto
Gastric Cancer, Gastric Metaplasia, Gastric Dysplasia
12/23
12/23
NCT02863783: EUS Fiducial for Pancreas Surgery

Active, not recruiting
N/A
20
US
EUS with Fiducial
University of Southern California
Pancreatic Neoplasms
12/23
02/24
NCT02863770: Contrast EUS of the Pancreas

Recruiting
N/A
150
US
EUS enhanced with contrast to evaluate pancreas
University of Southern California
Pancreatic Neoplasms, Pancreatitis, Pancreatic Cyst
04/24
04/24
NCT04932785: Regular vs. Clear Liquid Diet for Mild to Moderate Acute Pancreatitis

Recruiting
N/A
150
US
Regular diet, Clear Liquid Diet
University of Southern California
Pancreatitis, Diet, Food, and Nutrition, Diet, Pancreatic Disease, Enteral Nutrition
06/24
07/24
DREAM-ON, NCT06401577: Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

Not yet recruiting
N/A
800
US
Dexcom Continuous Glucose Monitor (CGM)
Milton S. Hershey Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Benaroya Research Institute, Cedars-Sinai Medical Center, University of Southern California, Indiana University, Johns Hopkins University, Ohio State University, Stanford University, University of Florida, AdventHealth, University of Illinois at Chicago, Northwestern University, University of Minnesota, University of Pittsburgh
Acute Pancreatitis
12/26
03/27
NCT03536247: Papillary Balloon Dilation Versus Intraductal Lithotripsy

Recruiting
N/A
90
US
Initial therapy with papillary balloon dilation, papillary dilation, Initial therapy with intraductal lithotripsy
University of Southern California
Choledocholithiasis
12/24
12/24
SHARP, NCT03609944: SpHincterotomy for Acute Recurrent Pancreatitis

Active, not recruiting
N/A
181
Canada, US
ERCP with miES, EUS
Oregon Health and Science University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pancreatitis, Pancreas Divisum, Pancreatitis, Acute, Pancreatitis Idiopathic, Pancreas Inflamed
02/25
08/25
DREAM, NCT05197920: Diabetes RElated to Acute Pancreatitis and Its Mechanisms

Recruiting
N/A
800
US
Milton S. Hershey Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Benaroya Research Institute, Cedars-Sinai Medical Center, University of Southern California, Indiana University, Johns Hopkins University, Ohio State University, Stanford University, University of Florida, AdventHealth, University of Illinois at Chicago, Northwestern University, University of Minnesota, University of Pittsburgh
Acute Pancreatitis
04/25
04/25
NCT05357599: The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis

Not yet recruiting
N/A
30
NA
EUS
University of Southern California
Cirrhosis, Compensated Cirrhosis, Portal Hypertension
05/25
07/25
NCT05423964: Impact of AI on Trainee ADR

Recruiting
N/A
25
US
AI use in Endoscopy Room, Non-AI use Standard of Care endoscopy room
University of Southern California
Adenoma, Adenoma Colon, Colorectal Cancer
06/25
09/25
NCT02196935: Los Angeles Prospective GI Biliary and EUS Series

Recruiting
N/A
2500
US
clinical course
University of Southern California
Biliary Disease, Pancreatitis, Gastrointestinal Neoplasms
12/25
12/25
MoSAIC, NCT05878236: iMmune SignAtures and Clinical outComes in AP

Recruiting
N/A
198
US
CyTOF Analysis
Ohio State University, University of Pittsburgh, University of Illinois at Chicago, University of Southern California, Benaroya Research Institute
Acute Pancreatitis
12/26
12/27
Pandol, Stephen
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
ALLIANCE, NCT05664880: A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

Recruiting
1
24
US
Paricalcitol, Placebo
Cedars-Sinai Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Pancreatitis
06/25
06/26
SMV in CP, NCT05771675: Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis

Not yet recruiting
1
90
US
Simvastatin, Placebo
Cedars-Sinai Medical Center, United States Department of Defense
Recurrent Acute Pancreatitis, Chronic Pancreatitis
12/25
06/26
PROCEED, NCT04753255: Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies, the Study

Recruiting
N/A
1820
US
Biospecimen Collection, Computed Tomography with Contrast, Contrast Enhanced Computed Tomography, CONTRAST ENHANCED CT SCAN, Contrast-enhanced Computed Tomography, CT Scan With Contrast, CT with Contrast, Contrast-enhanced Magnetic Resonance Imaging, CONTRAST ENHANCED MRI, Contrast-enhanced MRI, Dual X-ray Absorptiometry, BMD scan, bone mineral density scan, DEXA, DEXA Scan, dual energy x-ray absorptiometric scan, Dual Energy X-ray Absorptiometry, Dual X-Ray Absorptometry, DXA, DXA SCAN, Endoscopic Ultrasound, endosonography, EUS, Esophagogastroduodenoscopy, EGD, Questionnaire Administration
M.D. Anderson Cancer Center
Acute Pancreatitis, Chronic Pancreatitis
03/22
03/22
NCT06362187: VR Pilot for Pancreatitis

Recruiting
N/A
20
US
Gut Directed VR, Sham Control VR
Cedars-Sinai Medical Center
Chronic Pancreatitis, Recurrent Pancreatitis
05/25
05/26
DREAM-ON, NCT06401577: Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

Not yet recruiting
N/A
800
US
Dexcom Continuous Glucose Monitor (CGM)
Milton S. Hershey Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Benaroya Research Institute, Cedars-Sinai Medical Center, University of Southern California, Indiana University, Johns Hopkins University, Ohio State University, Stanford University, University of Florida, AdventHealth, University of Illinois at Chicago, Northwestern University, University of Minnesota, University of Pittsburgh
Acute Pancreatitis
12/26
03/27
DREAM, NCT05197920: Diabetes RElated to Acute Pancreatitis and Its Mechanisms

Recruiting
N/A
800
US
Milton S. Hershey Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Benaroya Research Institute, Cedars-Sinai Medical Center, University of Southern California, Indiana University, Johns Hopkins University, Ohio State University, Stanford University, University of Florida, AdventHealth, University of Illinois at Chicago, Northwestern University, University of Minnesota, University of Pittsburgh
Acute Pancreatitis
04/25
04/25
NCT04700488: Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
N/A
36
US
6D-MRI
Cedars-Sinai Medical Center
PDAC - Pancreatic Ductal Adenocarcinoma
01/26
01/26
Abtin, Fereidoun
CYBRID-01, NCT05478538: Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Recruiting
N/A
200
US
Core Needle or Forceps Biopsy
Elephas, Beaufort CRO
Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
12/26
12/26
Xiao, Zhijian
CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia

Recruiting
3
170
RoW
IMM01, Timdarpacept, Azacitidine, Placebo
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Chronic Myelomonocytic Leukemia
10/26
10/29
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Recruiting
3
552
RoW
Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA)
TJ Biopharma Co., Ltd.
Myelodysplastic Syndromes(MDS)
03/27
03/27
TQ05105-â…¡-01, NCT05020652: A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Recruiting
2
105
RoW
TQ05105 tablets, Hydroxycarbamide tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Moderate and High Risk Myelofibrosis
03/23
09/23
AK117-205, NCT06196203: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Recruiting
2
90
US, RoW
AK117, Placebo, Azacitidine
Akeso
Higher-risk Myelodysplastic Syndromes
01/26
06/26
NCT06457425: Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial

Recruiting
2
75
RoW
Flonoltinib 50mg, Flonoltinib 100mg, Ruxolitinib
Chengdu Zenitar Biomedical Technology Co., Ltd
MF,PMF,PPV-MF,PET-MF
05/26
07/26
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Checkmark Efficacy data from trial in combination with azacitidine for MDS
Sep 2022 - Sep 2022: Efficacy data from trial in combination with azacitidine for MDS
Checkmark Data from a study in combination with azacitidine for MDS at ESMO 2022
Sep 2022 - Sep 2022: Data from a study in combination with azacitidine for MDS at ESMO 2022
Completed
1/2
105
RoW
TJ011133
TJ Biopharma Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)
12/23
12/23
HATCH, NCT04691141: A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)

Terminated
1/2
15
RoW
ATG-016
Shanghai Antengene Corporation Limited
Myelodysplastic Syndrome
09/23
09/23
BC3402-104, NCT05970822: Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Recruiting
1b
32
RoW
BC3402, Azacitidine
Biocity Biopharmaceutics Co., Ltd.
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
03/25
12/25
NCT04485065: Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Suspended
1
120
RoW
IBI188+azacitidine
Innovent Biologics (Suzhou) Co. Ltd.
Myelodysplastic Syndromes
12/23
08/24
Wang, Tisha
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting
3
160
Europe, Canada, Japan, US, RoW
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo
Savara Inc., Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis
11/23
11/24
Arevalo, Melissa
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
SYCAMORE, NCT05085561: The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

Active, not recruiting
2
62
US
REC-994, Placebo
Recursion Pharmaceuticals Inc.
Cerebral Cavernous Malformation
12/25
12/25
NCT05841706: Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

Recruiting
1
10
US
Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL), PRBC Transfusion, Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL), Computed Tomography, CAT, CAT Scan, CAT scan, CAT Scan, Computed Axial Tomography, Computed Tomography, computed tomography, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Radiographic Imaging, Radiography, RG, Static X-Ray, X-RAY, X-Ray, X-Ray, X-Ray, X-Ray, Biospecimen Collection, Biological Sample Collection, Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection, Survey Administration, Pancreatectomy
Jonsson Comprehensive Cancer Center
Resectable Pancreatic Carcinoma
04/25
04/26
Livingston, Edward
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT05841706: Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

Recruiting
1
10
US
Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL), PRBC Transfusion, Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL), Computed Tomography, CAT, CAT Scan, CAT scan, CAT Scan, Computed Axial Tomography, Computed Tomography, computed tomography, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Radiographic Imaging, Radiography, RG, Static X-Ray, X-RAY, X-Ray, X-Ray, X-Ray, X-Ray, Biospecimen Collection, Biological Sample Collection, Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection, Survey Administration, Pancreatectomy
Jonsson Comprehensive Cancer Center
Resectable Pancreatic Carcinoma
04/25
04/26
Lofftus, Serena
POINT-B, NCT05078398: Postoperative Opt-In Narcotics Treatment in Breast

Recruiting
N/A
240
US
POINT Protocol, Usual care
University of California, Los Angeles
Breast Cancer, Breast Surgery, Opioid Use
01/25
02/25

Download Options